Researchers at City of Hope have developed a small molecule called AOH1996 that targets a specific protein variant essential for cancer cell DNA replication. The drug has shown the ability to kill various solid tumor cells in laboratory settings while sparing healthy tissue.
TLDR: Scientists at City of Hope have created a targeted chemotherapy molecule, AOH1996, which attacks a previously undruggable protein variant in solid tumors. By disrupting DNA repair in cancer cells, the treatment shows promise across multiple cancer types and is currently undergoing Phase 1 clinical trials.
Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, have developed a targeted chemotherapy molecule that appears to annihilate all solid tumors in preclinical research. The molecule, known as AOH1996, targets a cancerous variant of a protein called proliferating cell nuclear antigen (PCNA). In its mutated form, PCNA is critical for DNA replication and the repair of expanding tumors. This breakthrough offers a potential new avenue for treating a wide array of cancers that have traditionally been difficult to target without significant side effects.
For decades, PCNA was considered undruggable because it is essential for the survival of healthy cells. However, the team led by Professor Linda Malkas identified a specific region in PCNA that is uniquely altered in cancer cells. This discovery allowed them to design a molecule that specifically targets the cancerous version of the protein while leaving healthy cells unaffected. The research, published in the journal Cell Chemical Biology, represents the culmination of 20 years of laboratory work and rigorous testing.
AOH1996 works by disrupting the cell reproductive cycle through a process that targets the intersection of transcription and replication. It prevents cells with damaged DNA from dividing and from replicating their faulty DNA. This mechanism leads to programmed cell death, or apoptosis, in cancer cells. Because the molecule targets a protein that is fundamental to the growth of all solid tumors, it has shown efficacy in treating cells derived from breast, prostate, brain, ovarian, lung, and skin cancers in laboratory models.
In laboratory tests, the molecule was effective as a standalone treatment and in combination with other chemotherapy drugs. When used in combination, AOH1996 made cancer cells more susceptible to chemical agents that cause DNA or chromosome damage, such as cisplatin. This suggests that the molecule could eventually be used in polytherapy regimens to enhance the effectiveness of existing treatments while potentially reducing the necessary dosage of more toxic drugs. The ability to sensitize tumors to existing therapies could be a game-changer for patients with resistant cancer strains.
The development of AOH1996 was inspired by a young patient named Anna Olivia Healey, who died from neuroblastoma. The molecule’s name, AOH1996, incorporates her initials and birth year to honor her memory. The research team focused on creating a therapy that could address the high recurrence rates and limited treatment options for pediatric cancers, though the applications have since expanded to include a broad spectrum of adult solid tumors. This personal connection has driven the team through two decades of complex molecular engineering.
A Phase 1 clinical trial is currently underway at City of Hope to test the safety and side effects of the molecule in humans. This initial phase involves patients with recurrent solid tumors who have not responded to standard treatments. Researchers are monitoring the participants to determine the maximum tolerated dose and to observe any early signs of anti-tumor activity. The transition from animal models to human subjects is a critical step in validating the preclinical success observed in the lab.
If the clinical trials prove successful, AOH1996 could represent a significant shift in oncology. By targeting a protein that was previously thought to be inaccessible to drugs, the research opens new pathways for precision medicine. Future studies will focus on understanding the long-term effects of the molecule and its potential to prevent cancer recurrence by eliminating dormant cancer cells that harbor the mutated PCNA protein. The team is also exploring whether the molecule can be adapted to target other essential proteins that undergo similar mutations in malignant environments.
Susan Carter serves as a Senior Correspondent for Just Right News, where she leads the network’s comprehensive coverage of Health, Medicine, and Public Policy. With a career dedicated to dissecting the complexities of the American healthcare system, Susan brings a principled perspective to the most pressing debates of the day. Her reporting is characterized by a commitment to individual liberty, fiscal responsibility, and a healthy skepticism of government overreach, making her a vital voice for audiences seeking clarity in an increasingly regulated landscape.
Raised in Minneapolis, Minnesota, Susan’s professional outlook is deeply informed by the values of the American heartland. Growing up in the Twin Cities, she witnessed firsthand the importance of community-driven solutions and the resilience of the individual. This Midwestern foundation instilled in her a firm belief that the best answers to public policy challenges often come from local innovation and personal responsibility rather than top-down federal mandates. Her background allows her to translate complex legislative jargon into stories that resonate with families who value common sense and local autonomy.
Now based in Baltimore, Maryland, Susan operates from a unique vantage point at the intersection of medical innovation and urban policy. Living and working in a city renowned for its world-class medical institutions and significant public health challenges, she has a front-row seat to the realities of the modern healthcare landscape. Her proximity to these hubs of research and policy allows her to scrutinize how government intervention affects the quality of care and the freedom of medical professionals. In Baltimore, she sees the tangible results of policy decisions, using the city as a lens through which to examine the broader national health debate and the impact of federal spending on local communities.
As the lead for the acclaimed feature series “The Cost of Care,” Susan dives deep into the economic realities facing patients and providers alike. Her work focuses on the necessity of price transparency, the benefits of market competition, and the preservation of the sacred doctor-patient relationship. She is a staunch advocate for the idea that a well-informed public is the best defense against bureaucratic inefficiency. Through this series, she has exposed the hidden drivers of rising medical expenses, always seeking to empower the individual consumer over the massive institution.
Susan’s reporting on public policy is characterized by a commitment to rigorous inquiry and a focus on constitutional limits. Whether she is analyzing new pharmaceutical regulations, investigating the impact of federal health mandates, or exploring the future of medical technology, her goal remains the same: to provide Just Right News audiences with the facts they need to navigate a complex world. By blending her Midwestern sensibilities with the insights gained from her base in Maryland, Susan Carter has become a trusted authority for those who believe that personal freedom and public health are inextricably linked. Her work continues to challenge the status quo, advocating for a system that respects the taxpayer and prioritizes the patient.